# AEON catalysts: AEON Biopharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aeon/catalysts

> AEON Biopharma, Inc. (AEON) has no upcoming catalysts in this calendar. The latest recorded is the AEON Biopharma, Inc. earnings report, August 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AEON Biopharma, Inc. |
| Ticker | AEON (NYSE) |
| SEC CIK | 1837607 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aeon |

## Cash runway

Cash $3.4M as of 2026-06-30; quarterly burn $3.7M; about 2.8 months of runway at that rate (XBRL company facts, accession 0001837607-26-000062).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2021 | [ABP-450 trial start](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed | "The FDA allowed our Investigational New Drug application, or IND, for ABP-450, supporting our clinical trials in the preventative treatment for migraine, to proceed in October 2020, and we began treating patients in our Phase 2 clinical study beginning in March 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1837607/000183760724000093/aeon-20240930x10q.htm)) |
| Sep 2022 | [ABP-450 topline data readout](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed, met | "Topline data from the Phase 2 cervical dystonia study, released in September 2022, showed that ABP-450 met all primary endpoints and a number of other key secondary endpoints, supporting the further development of ABP-450 in reducing signs and symptoms associated with cervical dystonia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000066/aeon-20250630x10q.htm)) |
| May 3, 2024 | [ABP-450 interim data readout](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed, missed | "On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000085/aeon-20250930x10q.htm)) |
| November 13, 2024 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/aeon-20241113xex99.htm)) |
| March 24, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Fourth Quarter 2024 and Full Year Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/aeon-20250324xex99.htm)) |
| May 14, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/aeon-20250514xex99.htm)) |
| August 12, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/aeon-20250812xex99d1.htm)) |
| November 14, 2025 | [ABP-450 earnings report](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed | "AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm)) |
| November 19, 2025 | [ABP-450 interim data readout](https://sec-api.dev/pdufa/abp-450) | AEON |  | scheduled | "- FDA Type 2a meeting scheduled for November 19, 2025 to review AEON's analytical development plan and initial data -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114xex99d1.htm)) |
| March 30, 2026 | [ABP-450 earnings report](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed | "AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/aeon-20260330xex99d1.htm)) |
| May 14, 2026 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/aeon-20260514xex99d1.htm)) |
| August 12, 2026 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812xex99d1.htm)) |

## Drugs

- [ABP-450](https://sec-api.dev/pdufa/abp-450): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aeon/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AEON catalysts: AEON Biopharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aeon/catalysts

```bibtex
@misc{secapidev_companies_aeon_catalysts_20261116,
  title        = {AEON catalysts: AEON Biopharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aeon/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aeon_catalysts_20261116","title":"AEON catalysts: AEON Biopharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aeon/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
